Investors & Media

홈Investors & MediaNews release

News release

게시물 상세
News VasThera signs MoU with IBS for Study on the Mechanism of New Molecular Compounds
VasThera(choisy@vasthera.com)Date : 2022-09-27View : 314

 VasThera signs MoU with IBS for Study on the Mechanism of New Molecular Compounds

 

 

▲ VasThera-IBS Group Photo

Prev Dr. Sang Won Kang attended a business exchange meeting at the Korea Biotech Industry Organization
Next VasThera’s Dr. Sang Won Kang to Present at the 2022 BIO International Convention
TOPTOP
검색 닫기